Pfizer’s Pfizer XR is still $20 cheaper than the $10 version
Pfizer is not exactly known for making high-end drugs.
It made its name in the 1970s as a maker of generic drugs and then developed its own brand of branded generics for people like the US government, and for a time even the US military.
But it also made a name for itself in the pharma world in the mid-2000s when it started making cheaper versions of its own generics, as well as making some brand-name drugs for hospitals and pharmaceutical firms.
That led to the company’s recent move into generic drug pricing, which is currently controlled by the Federal Trade Commission.
Pfizer has been making generic drugs for more than two decades, but the generic version of its popular drug rx was still $10 cheaper than its generic equivalent in the United States in the past year.
That’s according to data from the company and a recent study by the consulting firm Avalere Health.
The PfizerXR was $10.99 more expensive than the generic equivalent, which was $17.39.
That means that for the first two months of the year, Pfizer was still selling a generic version for less than $10 a pill.
The company also announced a deal with the US Food and Drug Administration (FDA) on Tuesday to make some of the generic versions cheaper for consumers.
This isn’t the first time that Pfizer, the company that is most well-known for its powerful blockbuster drug Sovaldi, has been moving into generic pricing.
In 2014, Pfizers XR was sold for $19.99, a 20 percent discount.
That same year, its generic XR version was $11.99 less expensive.
But Pfizer also announced that it would be selling the XR generic versions for $8.99 and $7.99 a pill, respectively.
Both versions were cheaper than generic versions of Sovaldi.